Targeting BCL-2 Family Members in the Cell Death Pathway to Treat Head and Neck Cancer
Head and neck cancer accounts for approximately 3 percent of all cancers in the United States, and over 90% of them are head and neck squamous cell carcinoma (HNSCC). Chemotherapeutic drugs that treat HNSCC can activate BCL-2 family dependent apoptosis. Pro-apoptotic NOXA induced by adenovirus (Ad-N...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
VCU Scholars Compass
2018
|
| Subjects: | |
| Online Access: | https://scholarscompass.vcu.edu/etd/5352 https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=6435&context=etd |